The ALLIANCE trial is the first randomized blinded trial to investigate tenofovir alafenamide vs tenofovir disoproxil fumarate in treatment-naive individuals who have comorbid HIV/hepatitis B virus (HBV) infection.
The ALLIANCE trial from Gilead was 1 of 6 studies highlighted in a pre-AIDS 2022 press conference on July 27, 2022. The phase 3 study is currently investigating the safety and effectiveness of the triplet regimen of bictegravir/emtricitabine (FTC)/tenofovir alafenamide (TAF) vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) among persons living with comorbid HIV/hepatitis B virus infection not yet on a regular treatment regimen for these conditions.
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, and principal investigator on the study, presented the 48-week ALLIANCE findings Friday.
Transcript
Can you introduce yourself and tell us about your work?
My name is Anchalee Avihingsanon. I am in infectious disease, working in Thailand. I’m working with men with HIV, hepatitis B, tuberculosis, and also all common comorbidities in HIV-infected patients—a group [with] HIV and coinfection, and HIV and comorbidity, and also hepatitis B and C and tuberculosis, with and without HIV. That’s my main research. I’m a senior physician at the HIV-NAT, Thai Red Cross AIDS Research Centre. HIV-NAT is a organization working with the Netherlands, Australia, and Thailand; it’s a collaboration in HIV resources. I’m also working with the AIDS Clinical Trial Group, the ACTG group, in the US as a clinical research site [inaudible] for what we call the CRS site, for ACGC study.
Can you provide an overview of the ALLIANCE study and its principal findings?
The ALLIANCE study is a randomized control trial comparing TAF vs TDF in HIV infection coinfected with hepatitis B in adults initiating first-line ART [antiretroviral treatment]. This study is a placebo control. The patients were randomized to get either bictegravir/FTC/TAF vs dolutegravir plus FTC and TDF. And there was 1 placebo for each group. Also, [the trial was done] in a blinded fashion. The total study is 96 weeks, but for this presentation, we report through week 48 of the study—an interim analysis.
The study has 2 primary end points: the HIV and hepatitis B end points. We look at this because we know that TAF and TDF are widely used for HIV and hepatitis B, but we don’t know for sure how they work in HIV and hepatitis B coinfected patients. Usually hep B is difficult to treat compared to HIV actually, with the disease burden and disease severity, so this is quite important for us in terms of [being] investigators or clinicians—so the study is meaningful on that.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More